CSBR
CHAMPIONS ONCOLOGY, INC.
NASDAQ · Healthcare · Biotechnology · US
$4.69
−0.21%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.79
From 52W high−39.87%
Volume14757.00
Market cap$65.28M
P/E (TTM)—
P/S (TTM)1.1x
Div yield—
Key dataOct 19, 2026
Open
$4.79
From 52W high
−39.87%
Volume
14757.00
Market cap
$65.28M
ValuationView details →
P/E (Fwd)
42.6x
EV/EBITDA
162.1x
P/E (TTM)
—
RSI (14)
41.5
MomentumView details →
1D Return
−0.21%
YTD Return
−31.48%
SummaryUpdated Jul 1, 2026
Champions Oncology, Inc. (NASDAQ:CSBR) is a biotechnology company founded in 1985 and headquartered in Hackensack, New Jersey. Originally incorporated as Champions Biotechnology, the company changed its name to Champions Oncology in April 2011 to better reflect its focus on cancer research. The company has been publicly traded since its IPO in February 2007. Champions Oncology specializes in developing personalized cancer research solutions and technology platforms that help pharmaceutical and biotechnology companies advance their oncology drug development programs.
Similar companies
Latest newsMore news →
Champions Oncology reported first-quarter fiscal 2027 revenue of $15.2 million, up 8.8% year over year, with oncology services margin of 51% and adjusted EBITDA of $671,000.39d agoChampions Oncology reported record annual revenue of $59.4 million for fiscal year 2026, with fourth quarter revenue of $13.8 million and positive adjusted EBITDA for the fourth consecutive quarter.84d ago